ANAPTYSBIO, INC. Debt Securities, Available-for-sale, Amortized Cost
ANAPTYSBIO, INC. (ANAB) had Debt Securities, Available-for-sale, Amortized Cost of $80.05 million as of 2026-06-30, per its 10-KT filed 2026-09-21.
Financial Statements › Notes › Credit Losses
us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis · last filed 2026-09-21
- 2026-06-30: Debt Securities, Available-for-sale, Amortized Cost $80.05M.
- 2026-03-31: Debt Securities, Available-for-sale, Amortized Cost $37.92M.
- 2025-12-31: Debt Securities, Available-for-sale, Amortized Cost $73.26M.
- 2025-09-30: Debt Securities, Available-for-sale, Amortized Cost $146.57M.
| Period end | Debt Securities, Available-for-sale, Amortized Cost |
|---|---|
| 2026-06-30 | $80.05M 10-KT · filed 2026-09-21 |
| 2026-03-31 | $37.92M 10-Q · filed 2026-05-12 |
| 2025-12-31 | $73.26M 10-KT · filed 2026-09-21 |
| 2025-09-30 | $146.57M 10-Q · filed 2025-11-04 |
| 2025-06-30 | $249.21M 10-Q · filed 2025-08-06 |
| 2025-03-31 | $288.93M 10-Q · filed 2025-05-05 |
| 2024-12-31 | $302.21M 10-K · filed 2026-03-03 |
| 2024-09-30 | $265.48M 10-Q · filed 2024-11-05 |
| 2024-06-30 | $321.84M 10-Q · filed 2024-08-05 |
| 2024-03-31 | $316.86M 10-Q · filed 2024-05-09 |
| 2023-12-31 | $382.56M 10-K · filed 2025-02-27 |
| 2023-09-30 | $429.10M 10-Q · filed 2023-11-02 |
| 2023-06-30 | $456.92M 10-Q · filed 2023-08-07 |
| 2023-03-31 | $434.58M 10-Q · filed 2023-05-11 |
| 2022-12-31 | $517.91M 10-K · filed 2024-03-11 |
| 2022-09-30 | $537.73M 10-Q · filed 2022-11-08 |
| 2022-06-30 | $507.58M 10-Q · filed 2022-08-08 |
| 2022-03-31 | $432.63M 10-Q · filed 2022-05-04 |
| 2021-12-31 | $119.68M 10-K · filed 2023-03-01 |
| 2021-09-30 | $52.97M 10-Q · filed 2021-11-04 |
| 2021-06-30 | $64.05M 10-Q · filed 2021-08-09 |
| 2021-03-31 | $103.17M 10-Q · filed 2021-05-04 |
| 2020-12-31 | $160.54M 10-K · filed 2022-03-07 |
| 2020-09-30 | $164.90M 10-Q · filed 2020-11-04 |
| 2020-06-30 | $170.07M 10-Q · filed 2020-08-10 |
| 2020-03-31 | $246.03M 10-Q · filed 2020-05-06 |
| 2019-12-31 | $256.97M 10-K · filed 2021-02-25 |
| 2019-09-30 | $260.80M 10-Q · filed 2019-11-08 |
| 2019-06-30 | $325.58M 10-Q · filed 2019-08-08 |
| 2019-03-31 | $386.14M 10-Q · filed 2019-05-07 |
| 2018-12-31 | $404.48M 10-K · filed 2019-02-28 |
| 2018-09-30 | $221.88M 10-Q · filed 2018-11-08 |
| 2018-06-30 | $246.75M 10-Q · filed 2018-08-07 |
| 2018-03-31 | $243.37M 10-Q · filed 2018-05-08 |
| 2017-12-31 | $251.43M 10-K · filed 2018-03-05 |
| 2017-09-30 | $90.09M 10-Q · filed 2017-11-07 |
| 2017-06-30 | $89.58M 10-Q · filed 2017-08-10 |
| 2017-03-31 | $28.69M 10-Q · filed 2017-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |